Biogen (BIIB) PT Lowered to $262 at Needham & Company

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Biogen (BIIB) PT Lowered to $262 at Needham & Company

Stifel Reiterates Hold Rating on Biogen (BIIB), Notes CMS Decision "Closes The Door" for Aduhelm Coverage

April 8, 2022 6:07 AM EDT

Stifel analyst Paul Matteis reiterated a Hold rating on Biogen (NASDAQ: BIIB), following the final CMS coverage decision for beta amyloid mAbs.

The analyst notes: "CMS' final coverage decision for beta amyloid mAbs appears to be largely in-line with expectations--not much different from the... More

Biogen (BIIB) PT Lowered to $240 at Oppenheimer

April 8, 2022 5:07 AM EDT

Oppenheimer analyst Jay Olson lowered the price target on Biogen (NASDAQ: BIIB) to $240.00 (from $285.00) while maintaining a Outperform rating.... More

After-Hours Stock Movers 04/07: (MDVL) (WDFC) (PSFE) Higher; (BIIB) (CPT) Lower (more...)

April 7, 2022 6:03 PM EDT

After-Hours Stock Movers:

MedAvail Holdings, Inc. (MDVL) 53% HIGHER; adds to today's 64% intra-day gains on carried-over momentum.

WD-40 Co. (NASDAQ: WDFC) 10% HIGHER; postedQ2 EPS of $1.41, $0.39 better than the analyst estimate of $1.02. Revenue for the quarter came in at $130 million... More

Biogen (BIIB) Alzheimer's Drug Coverage To Be Limited To Patients In Trials: CMS

April 7, 2022 4:49 PM EDT

(Updated - April 7, 2022 4:55 PM EDT)

Biogen (NASDAQ: BIIB) shares were active after the market close on Thursday after CMS finalized its decision to pay for its Alzheimer's drug Aduhelm only in specified clinical trials, limiting payments.

... More